Embleema Inc.

Embleema Inc. is a healthcare technology company that specializes in enhancing precision medicine through a no-code platform for observational research, integrating various data types for advanced clinical studies. Founded in 2017 in Metuchen, US, Embleema Inc. focuses on creating a platform for observational research.

The company has not undergone any significant pivots but has raised USD 3. 00 mn in Series A funding on February 1, 2019, led by Pharmagest Interactive SA and Techstars. It has completed a total of 2 deals. The CEO is Robert Chu, who is instrumental in the company's operations.

Embleema specializes in providing a comprehensive platform for observational research aimed at advancing precision medicine. The core product offerings include a flexible, no-code platform that allows for the rapid configuration of observational studies and registries, integrating diverse data types such as electronic health records (EHR), imaging, molecular data, and patient-reported outcomes (PRO). This platform enhances study execution by utilizing advanced workflows and automated data capture, thereby accelerating data availability. Key end users include clinical research organizations, academic institutions, and pharmaceutical companies, particularly in the U.

S. , Europe, and Asia. Embleema has established partnerships with top research institutions and regulatory bodies, facilitating a collaborative approach that engages patients as research partners while ensuring high-quality evidence generation through built-in quality controls. The revenue model of Embleema is primarily driven by B2B transactions, wherein the company provides its platform and services to research sponsors and clinical sites.

Clients engage in subscriptions for access to the platform, which is designed to streamline the execution of observational studies and improve patient engagement through modern app interfaces. Revenue is generated through the deployment of the platform for specific studies, which may involve tailored configurations to meet the unique needs of each research initiative. The company emphasizes its ability to quickly implement studies, reducing costs and timelines for its clients. Flagship services include advanced data collection and integration features that ensure compliance and rigor in research outcomes, catering to the evolving demands of the life sciences sector.

In February 2019, Embleema Inc. raised USD 3. 00 mn in Series A funding to support its commercial scale-up and the advancement of blockchain-based applications for patients and pharmacies. The company plans to leverage this funding to enhance its product offerings and expand into new geographic markets, focusing on regions such as Europe and Asia by mid-2024.